论文部分内容阅读
目的观察多烯磷脂酰胆碱胶囊联合决明降脂片治疗非酒精性脂肪肝临床疗效及安全性。方法 62例非酒精性脂肪肝患者随机分为对照组31例与试验组31例。对照组给予多烯磷脂酰胆碱胶囊456 mg,每日3次,口服;试验组在对照组的基础上给予决明降脂片2.7 g,每日3次,口服。2组患者均治疗2个月。比较2组患者的临床疗效、瘦素、肝功能水平及药物不良反应发生情况。结果治疗后,试验组总有效率为87.10%(27/31例),对照组为64.52%(20/31例,P<0.05)。治疗后,对照组和试验组血清瘦素分别为(1.08±0.17),(0.76±0.89)μg·L~(-1),谷丙转氨酶分别为(50.82±5.59),(34.97±4.03)U·L~(-1),谷草转氨酶分别为(54.92±6.02),(40.25±4.53)U·L~(-1),总胆红素分别为(30.11±3.35),(27.89±3.09)μmol·L~(-1),直接胆红素分别为(18.02±2.01),(13.60±1.67)μmol·L~(-1),白蛋白分别为(35.92±4.45),(42.03±4.70)g·L~(-1),差异均有统计学意义(P<0.05)。试验组出现的药物不良反应有轻微胃肠道紊乱、眩晕头痛、皮疹,药物不良反应发生率为9.68%(3/31例);对照组出现的药物不良反应有眩晕头痛、眩晕头痛、皮疹、肝硬化,药物不良反应发生率为22.58%(7/31例),2组药物不良反应率差异无统计学意义(P>0.05)。结论多烯磷脂酰胆碱胶囊联合决明降脂片治疗非酒精性脂肪肝的临床疗效较高,安全性高。
Objective To observe the clinical efficacy and safety of polyene phosphatidylcholine capsules combined with Jindingjiang lipid-lowering tablets in the treatment of non-alcoholic fatty liver disease. Methods Sixty-two patients with non-alcoholic fatty liver were randomly divided into control group (31 cases) and experimental group (31 cases). The control group was given polyene phosphatidylcholine capsules 456 mg orally three times a day. The experimental group was given Cassia bismuthiobaricum tablets 2.7 g three times a day orally on the basis of the control group. Two groups of patients were treated for 2 months. The clinical efficacy, leptin, liver function and adverse drug reactions in two groups were compared. Results After treatment, the total effective rate was 87.10% (27/31) in the experimental group and 64.52% (20/31 cases, P <0.05) in the control group. After treatment, the levels of leptin in control group and experimental group were (1.08 ± 0.17) and (0.76 ± 0.89) μg · L -1, respectively. The alanine aminotransferases were (50.82 ± 5.59) and (34.97 ± 4.03) U · L -1 and aspartate aminotransferase were (54.92 ± 6.02) and (40.25 ± 4.53) U · L -1 respectively, total bilirubin were (30.11 ± 3.35) and (27.89 ± 3.09) μmol respectively · L -1 and direct bilirubin were (18.02 ± 2.01) and (13.60 ± 1.67) μmol·L -1, albumin were (35.92 ± 4.45) and (42.03 ± 4.70) g respectively · L ~ (-1), the differences were statistically significant (P <0.05). Adverse drug reactions in the test group were mild gastrointestinal disorders, dizziness headache, rash, adverse drug reactions occurred in 9.68% (3/31 cases); adverse drug reactions in the control group were dizziness headache, dizziness, headache, rash, The incidence of cirrhosis and adverse drug reactions was 22.58% (7/31 cases). There was no significant difference in adverse drug reaction between the two groups (P> 0.05). Conclusion Polyene phosphatidylcholine capsules combined with Cassia lipid-lowering tablets for the treatment of non-alcoholic fatty liver has high clinical efficacy and safety.